Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
The Fagerström Test for Nicotine Dependence as a Predictor of Smoking Abstinence
by
Russ, Cristina
, Yu, Ching-Ray
, Foulds, Jonathan
, Fagerström, Karl
, Yunis, Carla
in
Adult
/ Benzazepines - therapeutic use
/ Double-Blind Method
/ Female
/ Humans
/ Linear Models
/ Male
/ Middle Aged
/ Nicotinic Agonists - therapeutic use
/ ORIGINAL INVESTIGATIONS
/ Placebo Effect
/ Quinoxalines - therapeutic use
/ Randomized Controlled Trials as Topic
/ Smoking - drug therapy
/ Smoking Cessation - methods
/ Smoking Prevention
/ Surveys and Questionnaires
/ Tobacco Use Disorder - diagnosis
/ Tobacco Use Disorder - epidemiology
/ Tobacco Use Disorder - prevention & control
/ Varenicline
2012
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Fagerström Test for Nicotine Dependence as a Predictor of Smoking Abstinence
by
Russ, Cristina
, Yu, Ching-Ray
, Foulds, Jonathan
, Fagerström, Karl
, Yunis, Carla
in
Adult
/ Benzazepines - therapeutic use
/ Double-Blind Method
/ Female
/ Humans
/ Linear Models
/ Male
/ Middle Aged
/ Nicotinic Agonists - therapeutic use
/ ORIGINAL INVESTIGATIONS
/ Placebo Effect
/ Quinoxalines - therapeutic use
/ Randomized Controlled Trials as Topic
/ Smoking - drug therapy
/ Smoking Cessation - methods
/ Smoking Prevention
/ Surveys and Questionnaires
/ Tobacco Use Disorder - diagnosis
/ Tobacco Use Disorder - epidemiology
/ Tobacco Use Disorder - prevention & control
/ Varenicline
2012
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
The Fagerström Test for Nicotine Dependence as a Predictor of Smoking Abstinence
by
Russ, Cristina
, Yu, Ching-Ray
, Foulds, Jonathan
, Fagerström, Karl
, Yunis, Carla
in
Adult
/ Benzazepines - therapeutic use
/ Double-Blind Method
/ Female
/ Humans
/ Linear Models
/ Male
/ Middle Aged
/ Nicotinic Agonists - therapeutic use
/ ORIGINAL INVESTIGATIONS
/ Placebo Effect
/ Quinoxalines - therapeutic use
/ Randomized Controlled Trials as Topic
/ Smoking - drug therapy
/ Smoking Cessation - methods
/ Smoking Prevention
/ Surveys and Questionnaires
/ Tobacco Use Disorder - diagnosis
/ Tobacco Use Disorder - epidemiology
/ Tobacco Use Disorder - prevention & control
/ Varenicline
2012
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
The Fagerström Test for Nicotine Dependence as a Predictor of Smoking Abstinence
Journal Article
The Fagerström Test for Nicotine Dependence as a Predictor of Smoking Abstinence
2012
Request Book From Autostore
and Choose the Collection Method
Overview
We explored the relationship between the Fagerström Test for Nicotine Dependence (FTND) and smoking abstinence rates in 10 randomized, double-blind placebo-controlled Phase 2-4 varenicline studies.
Participants were adult smokers (≥10 cigarettes/day) who were motivated to quit. Efficacy end points included continuous abstinence rate (CAR) for weeks 9-24 analyzed, by baseline FTND and Heaviness of Smoking Index (HSI) scores, and treatment. Data were analyzed using logistic regression models.
Overall, 2,763 varenicline (M [SD] FTND score: 5.6 [2.2]) and 2,229 placebo subjects (5.5 [2.1]) were included in the analysis. An increase of one unit in baseline FTND or HSI score decreased the odds of abstinence at Week 24 by 11% (odds ratio [OR] 0.89, 95% CI 0.86-0.92, p < .0001) and 18% (OR 0.82, 95% CI 0.79-0.87, p < .0001), respectively. Treatment had a significant impact on CAR 9-24: odds of abstinence were increased threefold for varenicline versus placebo (OR 3.3, 95% CI 2.8-3.8, p < .0001). There was no interaction between treatment and FTND (p = .98) or HSI score (p = .97) for CAR 9-24. The HSI score predicted abstinence outcome as effectively as the FTND score.
Abstinence rates decreased with increasing dependence scores. There was no interaction between treatment and baseline FTND or HSI score, suggesting that they have no effect on the efficacy of varenicline versus placebo. These results also suggest that the HSI may be as effective at predicting smoking cessation outcome as the whole FTND questionnaire.
Publisher
Oxford University Press
This website uses cookies to ensure you get the best experience on our website.